FDA Approves Teplizumab for Children 8 and Older With Stage 3 Type 1 Diabetes

The approval rests on data from the original phase 2 and 3 trials that demonstrated a median 2-year delay in insulin dependence among autoantibody-positive individuals. Pediatric extrapolation used pharmacokinetic modeling and safety data from 44 children enrolled in earlier studies rather than a dedicated pediatric RCT. Absolute delay in insulin start was 18 months versus 10 months in controls. Sanofi’s application encountered internal FDA friction when former CDER head Tracy Beth Høeg questioned staff conclusions on risk-benefit balance in younger patients. The episode highlights how political appointees can insert themselves into scientific reviews and how the accelerated review pathway launched under Marty Makary can compress timelines without new pediatric efficacy trials. Broader implications include pressure on health systems to implement autoantibody screening in children, a shift from reactive insulin management to proactive immune modulation. Real-world registries will be essential to determine whether the observed delay translates into reduced long-term complications such as retinopathy or nephropathy. Post-marketing requirements include a 5-year observational study tracking C-peptide preservation and infection rates in at least 300 treated children, with interim results due by 2029.